Alcon Inc. (SWX:ALC)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 29.78B |
| Revenue (ttm) | 7.97B |
| Net Income (ttm) | 853.34M |
| Shares Out | 494.40M |
| EPS (ttm) | 1.72 |
| PE Ratio | 35.07 |
| Forward PE | 23.08 |
| Dividend | 0.28 (0.47%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 760,264 |
| Average Volume | 1,239,865 |
| Open | 58.74 |
| Previous Close | 59.76 |
| Day's Range | 58.74 - 60.00 |
| 52-Week Range | 57.68 - 87.00 |
| Beta | 0.69 |
| RSI | 44.43 |
| Earnings Date | Nov 11, 2025 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
Alcon's (ALC) Proposed Acquisition Faces Major Opposition
Alcon's (ALC) Proposed Acquisition Faces Major Opposition
Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory ...
STAAR Surgical (STAA) Shareholders Advised to Reject Alcon's Acquisition Offer
STAAR Surgical (STAA) Shareholders Advised to Reject Alcon's Acquisition Offer
STAAR Surgical holders should vote against sale to Alcon, ISS says - report
Proxy advisers urge STAAR Surgical shareholders to reject Alcon's $1.5B acquisition. Learn key reasons and market impact before the Oct. 23 vote.
Broadwood Partners Comments on STAAR Surgical's Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR” or the “C...
Barclays Initiates Coverage on Alcon (ALC) with Equal-Weight Rating | ALC Stock News
Barclays Initiates Coverage on Alcon (ALC) with Equal-Weight Rating | ALC Stock News
Investor Group Opposes Alcon's Acquisition of STAAR Surgical (ALC)
Investor Group Opposes Alcon's Acquisition of STAAR Surgical (ALC)
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
Alcon (ALC) Faces Opposition in Staar Surgical Merger Deal
Alcon (ALC) Faces Opposition in Staar Surgical Merger Deal
STAAR Surgical (STAA): Proxy Adviser Urges Rejection of Alcon Deal
STAAR Surgical (STAA): Proxy Adviser Urges Rejection of Alcon Deal
Glass Lewis Advises Against Alcon (ALC) Acquisition of STAAR
Glass Lewis Advises Against Alcon (ALC) Acquisition of STAAR
STAAR Surgical holders should vote against sale to Alcon, Glass Lewis says
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, ha...
Broadwood Partners Questions Integrity of STAAR Surgical's Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today sent the following letter to the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (N...
Defender Capital Opposes STAAR Surgical's Proposed Acquisition By Alcon
(RTTNews) - Defender Capital, a long-term shareholder of STAAR Surgical Co. (STAA) holding approximately 1.5% of the Company's outstanding common stock, issued a statement opposing the proposed acquis...
Alcon's Proposed Acquisition of STAAR Faces Shareholder Opposition
Alcon's Proposed Acquisition of STAAR Faces Shareholder Opposition
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
CHARLOTTE, N.C. , Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1...
Yunqi Capital Challenges Proposed Sale of STAAR to Alcon (ALC)
Yunqi Capital Challenges Proposed Sale of STAAR to Alcon (ALC)
Yunqi Capital, One of STAAR Surgical Company's Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Judgment in Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Swiss Market Settles On Firm Note As Alcon, UBS Group Rise Sharply
(RTTNews) - The Switzerland market closed on a firm note on Friday, gaining in strength after a modestly positive start. Expectations of more monetary easing by the Federal Reserve, and optimism surro...
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breach...
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical's Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or...